Skip to main content
SpringerLink
Log in

Epidemiology, Pathology, Aetiological Factors, Prevention, Screening, Symptoms, and Signs

  • Chapter
Urological Cancer Management

  • 654 Accesses

Abstract

Urinary bladder cancer (or tumour) (BC or BT) had an estimated worldwide incidence of 430,000 new cases in 2012 comprising 330,000 men and 100,000 women approximately [1]. The associated specific mortality was 165,000 [1] in the world and 55,200 in the European Union and the United States alone [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D Bray, F. GLOBOCAN 2012. v1.0, cancer incidence and mortality worldwide: IARC Cancer Base no. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr

  2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49:1374–403.

    Article  CAS  PubMed  Google Scholar 

  3. American Cancer Society. Cancer facts and figures 2014. Atlanta: American Cancer Society; 2014. p. p. 22.

    Google Scholar 

  4. Brown ML, Riley GF, Schussler N, et al. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40:IV-104–17.

    Article  Google Scholar 

  5. Gupta P, Jain M, Kapoor R, Muruganandham K, Srivastava A, Mandhani A. Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol. 2009;25(2):207–10.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.

    Article  PubMed  Google Scholar 

  7. Yossepowitch O, Dalbagni G. Transitional cell carcinoma of the bladder in young adults: presentation, natural history and outcome. J Urol. 2002;168(1):61–6.

    Article  PubMed  Google Scholar 

  8. Poletajew S, Walędziak M, Fus L, et al. Urothelial bladder carcinoma in young patients is characterized by a relatively good prognosis. Ups J Med Sci. 2012;117(1):47–51.

    Article  PubMed Central  PubMed  Google Scholar 

  9. Fleshner NE, Herr HW, Stewart AK, Murphy GP, Mettlin C, Menck HR. The National Cancer Data Base report on bladder carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1996;78(7):1505–13.

    Article  CAS  PubMed  Google Scholar 

  10. Freedman ND, Silverman DT, Hollenbeck AR, Schatzkin A, Abnet CC. Association between smoking and risk of bladder cancer among men and women. JAMA. 2011;306:737–45 [Published correction appears in JAMA. 2011;306:2220].

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289–93.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Burger M, Catto JWF, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(1):234–41.

    Article  PubMed  Google Scholar 

  13. Lane DP. p53, guardian of the genome. Nature. 1992;358:15–6.

    Article  CAS  PubMed  Google Scholar 

  14. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 1993;85(1):53–9.

    Article  CAS  PubMed  Google Scholar 

  15. Rafnar T, Vermeulen SH, Sulem P, et al. European genome-wide association study identifies SLC14A1 as a new urinary bladder cancer susceptibility gene. Hum Mol Genet. 2011;20:4268–81.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  16. Zaghloul MS. Bladder cancer and schistosomiasis. J Egypt Nat Cancer Ins. 2012;24(4):151–9.

    Article  Google Scholar 

  17. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, IARC CancerBase No. 5, version 2.0. Lyon: IARC Press; 2004.

    Google Scholar 

  18. Quinta A, Carvalho AP, Oliveira M, Oliveira C, Ribeiro Santos A. Bladder adenocarcinoma 41 years after augmentation enterocystoplasty for tuberculosis. Arch Esp Urol. 2013;66(2):231–3.

    PubMed  Google Scholar 

  19. Tanguay C, Harvey I, Houde M, Srigley JR, Têtu B. Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases. Mod Pathol. 2003;16:512–4.

    Article  CAS  PubMed  Google Scholar 

  20. Bléoo SL, Godbout R, Rayner D, Tamimi Y, Moore RB. Leiomyosarcoma of the bladder in a retinoblastoma patient. Urol Int. 2003;71:118–21.

    Article  PubMed  Google Scholar 

  21. Zlotta AR, Roumeguere T, Kuk C, et al. Select screening in a specific high-risk population of patients suggests a stage migration toward detection of non-muscle-invasive bladder cancer. Eur Urol. 2011;59:1026–31.

    Article  PubMed  Google Scholar 

  22. Cummings KB, Barone JG, Ward WS. Diagnosis and staging of bladder cancer. Urol Clin North Am. 1992;19:455–65.

    CAS  PubMed  Google Scholar 

  23. Sultana SR, Goodman CM, Byrne DJ, Baxby K. Microscopic haematuria urological investigation using a standard protocol. Br J Urol. 1996;78:691–8.

    Article  CAS  PubMed  Google Scholar 

  24. Grossfeld GD, Wolf Jr JS, Litwan MS, et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician. 2001;63:1145–54.

    CAS  PubMed  Google Scholar 

  25. Pfister C, Roupret M, Wallerand H, Davin JL, Quintens H, Guy L, et al. Recommandations du CCAFU 2010: Tumeurs urothéliales. Prog Urol. 2010;20:S255–74.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Department, The Royal Hospital, Muscat, Oman

    Said Abdallah Al-Mamari & Salim Said Al-Busaidy

Authors
  1. Said Abdallah Al-Mamari
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salim Said Al-Busaidy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Said Abdallah Al-Mamari .

Editor information

Editors and Affiliations

  1. Urology Department, The Royal Hospital, Muscat, Oman

    Said Abdallah Al-Mamari

  2. Urology Department, The Royal Hospital, Muscat, Oman

    Salim Said Al-Busaidy

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Al-Mamari, S.A., Al-Busaidy, S.S. (2015). Epidemiology, Pathology, Aetiological Factors, Prevention, Screening, Symptoms, and Signs. In: Al-Mamari, S., Al-Busaidy, S. (eds) Urological Cancer Management. Springer, Cham. https://doi.org/10.1007/978-3-319-16301-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-16301-7_5

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-16300-0

  • Online ISBN: 978-3-319-16301-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation